1 - "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
2 - Clinical Emergency Hospital of Bucharest, Bucharest, Romania 3 "N.C. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania
3 - Universitary Emergency Central Military Hospital, Bucharest, Romania
4 - Academy of Romanian Scientists, Bucharest, Romania
5 - Ovidius University, Faculty of Medicine, Constanta, Romania
Received: September 30, 2018
Accepted: January 28, 2019
Two major trials, EMPA-REG OUTCOME trial (with Empagliflozin) and CANVAS trial (with Canagliflozin) have demonstrated the beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes at risk for heart failure. SGLT2 inhibitors possess a unique pharmacological profile and have shown a significant reduction of hospitalization for heart failure in diabetic patients, immediately after treatment commencement. It seems that their effects are beneficial both in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. SGLT2 inhibitors reduce cardiovascular endpoints in patients with diabetes and high cardiovascular risk, most likely through a reduction of heart failure-related events. Empagliflozin treatment exerts beneficial effects on vascular function and central haemodynamics. Various mechanisms seem to contribute to the beneficial effects of SGLT2 inhibitors in heart failure. Taking into consideration their cardiovascular benefits and the number of ongoing trials with these drugs, there is a possibility to expand their indication to nondiabetic patients with heart failure. This review focuses on the newest insights into the beneficial effects of SGLT2 inhibitors on the cardiovascular system.
Diaconu, C., Salmen, T., Găman, M.A., Bratu, O.G., Mischianu, D., Marcu, R.D., Suceveanu, A.I., Costache, R.S., & Stoian, A.P. (2025). Sglt2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?. Romanian Journal of Military Medicine, 122(1), 16-21.
Diaconu C, Salmen T, Găman MA, Bratu OG, Mischianu D, Marcu RD, et al. SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?. Rom J Mil Med. 2025;122(1):16-21.
Diaconu, C., Salmen, T., Găman, M.A., Bratu, O.G., Mischianu, D., Marcu, R.D., Suceveanu, A.I., Costache, R.S. & Stoian, A.P. 2025, 'SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: which are the benefits?', Romanian Journal of Military Medicine, vol. 122, no. 1, pp. 16-21.
